Cipla, India's third-largest generic drugmaker by sales, reported a 15.2% rise in second-quarter profit that beat estimates, driven by higher sales of its respiratory and cancer drugs in its key North America and India markets.

Earnings per Share (EPS) for Q2 stood at ₹ 3.85, reflecting a year-over-year increase of 34.15%. This positive performance has contributed to a market capitalization of ₹ 25676.06 Crores for Sumitomo Chemical India.

Indian consumer goods maker Marico reported second-quarter profit well above market estimates on Tuesday, propped up by price hikes undertaken to offset higher raw material prices.

Drug major Cipla on Tuesday reported a 17 per cent increase in consolidated net profit to Rs 1,303 crore for the second quarter ended September 2024, driven by robust sales across markets

Pharma major Cipla Ltd on Tuesday reported an 15.2% year-on-year rise in its consolidated net profit for the fiscal's second quarter ended September (Q2FY25) to ₹1,303.53 crore. The company had reported a profit of ₹1,

Cipla posted a 15.2% rise/decline in its net profit for the second quarter of the financial year, though shares were still in the red on Tuesday. What Happened: India’s third-largest pharmaceutical company said its net profit attributable to owners came in at ₹1,

Cipla is set to report a 3-6% revenue growth for the September quarter, as forecasted by four brokerages. The earnings for Q2FY25 will be announced on October 29, 2024. Estimates for net profit also show a potential increase of 4-5.